A study including almost 6000 people with hypertension revealed that the development of kidney disease is more likely among hypertensive patients who are also overweight or obese. When reviewed at baseline, none of the patients had chronic kidney disease; after 5 years, however, the disease was prevalent in 28% of patients with ideal body weight, 31% of patients considered overweight, and 34% of obese patients. Lead investigator Holly Kramer,MD, MPH, notes the association between obesity and risk of chronic kidney disease within the hypertensive population: "Obesity represents a constellation of risk factors mediated by insulin resistance, which we know increases cardiovascular risk."
Ms. Farley is a freelance medical writer based in Wakefield, RI.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs